Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020)
Forte Biosciences (FBRX) posted quarterly Non Operating Investment Income of -$10000.0 for Q1 2020, down 124.39% year-over-year from $41000.0 in Q2 2019, and up 69.7% quarter-over-quarter from -$33000.0 in Q4 2019.
Powered by 
Analysis
Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Non Operating Investment Income for 5 consecutive years, with -$10000.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Non Operating Investment Income fell 124.39% year-over-year to -$10000.0; the TTM figure through Mar 2020 stood at -$18000.0 (down 114.29% YoY), while the FY2019 annual figure was $33000.0, up 200.0% from the prior year.
- Non Operating Investment Income grew to -$10000.0 in Q1 2020 per FBRX's latest filing, from -$33000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $54000.0 in Q1 2016 and bottomed at -$74000.0 in Q1 2018.
- Historically, Non Operating Investment Income has averaged $3866.7 across 5 years, with a median of -$1000.0 in 2017.
- On a YoY basis, Non Operating Investment Income climbed as much as 1000.0% in 2018 and fell as far as 7300.0% in 2018.
- Forte Biosciences' Non Operating Investment Income stood at -$9000.0 in 2016, then plunged by 244.44% to -$31000.0 in 2017, then surged by 200.0% to $31000.0 in 2018, then tumbled by 206.45% to -$33000.0 in 2019, then jumped by 69.7% to -$10000.0 in 2020.
- Business Quant data shows FBRX's Non Operating Investment Income at -$10000.0 in Q1 2020, -$33000.0 in Q4 2019, and -$13000.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -10,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Sep 30, 2019 | -13,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Mar 31, 2018 | -74,000.00 |
| Dec 31, 2017 | -31,000.00 |
| Sep 30, 2017 | 4,000.00 |
| Jun 30, 2017 | -6,000.00 |
| Mar 31, 2017 | -1,000.00 |
| Dec 31, 2016 | -9,000.00 |
| Jun 30, 2016 | 13,000.00 |
| Mar 31, 2016 | 54,000.00 |